Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mallinckrodt Plc Ordinary Share (MNK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Mallinckrodt To Present At The Stifel 2017 Healthcare Conference

STAINES-UPON-THAMES, England , Oct. 18, 2017 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, Nov. 14,...

MNK : 32.42 (-1.22%)
Mallinckrodt To Present At The Stifel 2017 Healthcare Conference

Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, Nov. 14, 2017, at the Stifel 2017 Healthcare Conference, which takes place at the Lotte...

MNK : 32.42 (-1.22%)
Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today it will report fiscal 2017 third quarter earnings results for the period of July 1, 2017, to Sept. 29, 2017,...

MNK : 32.42 (-1.22%)
Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel

Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.

CELG : 121.33 (-10.76%)
ACAD : 36.32 (+1.37%)
MNK : 32.42 (-1.22%)
ADRO : 9.20 (-0.27%)
Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it will conduct a new Phase 4, multi-center, randomized, double blind, placebo-controlled study to further...

MNK : 32.42 (-1.22%)
Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor Briefing

Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, is holding its investor briefing today in New York City with presentations by Mallinckrodt executives Mark Trudeau, President and...

MNK : 32.42 (-1.22%)
Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor Briefing

STAINES-UPON-THAMES, United Kingdom , Oct. 4, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, is holding its investor briefing today in New York...

MNK : 32.42 (-1.22%)
Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy

Mallinckrodt plc (MNK) entered into a licensing agreement with NeuroproteXeon for the development and commercialization of the latter's investigational, pharmaceutical-grade xenon gas for inhalation therapy....

MNK : 32.42 (-1.22%)
REGN : 432.98 (-1.81%)
ADRO : 9.20 (-0.27%)
BIIB : 338.10 (-1.26%)
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development Product

Mallinckrodt plc (NYSE:MNK) today announced it has entered into a licensing agreement for development and commercialization of NeuroproteXeon's investigational, pharmaceutical-grade xenon gas for inhalation...

MNK : 32.42 (-1.22%)
Mallinckrodt (MNK) Closes InfaCare Pharmaceutical Buyout

Mallinckrodt (MNK) acquires privately-held InfaCare Pharmaceutical Corporation to diversify portfolio.

VRTX : 154.63 (+0.02%)
MNK : 32.42 (-1.22%)
REGN : 432.98 (-1.81%)
ALXN : 139.02 (-1.03%)
Featured Company News - Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical; Acquires Global Rights for Stannsoporfin

LONDON, UK / ACCESSWIRE / September 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Mallinckrodt PLC (NYSE: MNK), following which we have published...

MNK : 32.42 (-1.22%)
The Medicines Co. Continues to Focus on Pipeline Development

The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.

MDCO : 33.98 (-1.36%)
MNK : 32.42 (-1.22%)
REGN : 432.98 (-1.81%)
ALXN : 139.02 (-1.03%)
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States

Mallinckrodt plc (NYSE: MNK), an industry leader in the effort to address prescription drug diversion and misuse in the United States, today outlined its "Prescription for America's Opioid Epidemic" -...

MNK : 32.42 (-1.22%)
Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States

ST. LOUIS , Sept. 22, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), an industry leader in the effort to address prescription drug diversion and misuse in the United States , today outlined...

MNK : 32.42 (-1.22%)
Mallinckrodt Announces Election Of David Norton To Its Board Of Directors

Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, announced today the election of David Norton to the company's Board of Directors, effective immediately. Mr....

MNK : 32.42 (-1.22%)
Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon Pharma, Mylan, and Neurocrine Biosciences

If you want a Stock Review on MNK, HZNP, MYL, or NBIX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com have issued research...

MYL : 38.51 (+0.57%)
HZNP : 14.09 (-0.35%)
NBIX : 59.03 (+0.12%)
MNK : 32.42 (-1.22%)
Mallinckrodt Down as District Court Invalidates Inomax Patents

Shares of Mallinckrodt plc (MNK) were down 12.3% after a U.S. District Court invalidated 11 patents covering its second-largest product Inomax.

PX : 143.14 (+1.94%)
GILD : 81.21 (-0.47%)
MNK : 32.42 (-1.22%)
ADRO : 9.20 (-0.27%)
Mallinckrodt Falls 13.32% on Heavy Volume: Watch For Potential Rebound

Mallinckrodt (NYSE:MNK) traded in a range yesterday that spanned from a low of $35.10 to a high of $41.31. Yesterday, the shares fell 13.3%, which took the trading range below the 3-day low of $38.71...

MNK : 32.42 (-1.22%)
Stull, Stull & Brody Reminds Investors of Class Action Lawsuit on Behalf of Employee Benefit Plan Purchasers of Mallinckrodt plc Stock

Stull, Stull & Brody ("SS&B") reminds investors that a class action lawsuit was commenced in the United States District Court for the Eastern District of Missouri on behalf of purchasers of stock of Mallinckrodt...

MNK : 32.42 (-1.22%)
Neos Therapeutic has the Best Relative Performance in the Pharmaceuticals Industry (NEOS, IPXL, MDCO, ENDP, MNK)

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

ENDP : 7.72 (-2.03%)
MDCO : 33.98 (-1.36%)
IPXL : 21.25 (+1.19%)
MNK : 32.42 (-1.22%)
NEOS : 7.70 (+2.67%)

Van Meerten Stock Picks

My 5 Favorite NASDAQ 100 Stocks
This morning I wanted to find the 5 best NASDAQ 100 stocks that had the highest return in the past year, had consistent price appreciation and still looked like they had room to go.
AMAT +0.76 , NVDA -0.90 , ADSK +1.52 , MU +0.19 , LRCX +4.36
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 +0.21%) this morning are up +0.23% at a new record high on optimism that the Trump administration will be able to enact its tax reform plans after the Senate adopted a fiscal 2018 budget... Read More

Chart of the Day

Chart of the Day

LimeLight Networks (LLNW) is the Barchart Chart of the Day.  The Internet company has a Trend Spotter buy signal, a Weighted Alpha of 18.33+ and gained 149.71% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended Friday with most contracts 3 1/2 to 4 1/2 cents lower. The USDA announced private export sales of 125,000 MT of corn to Unknown Destinations, with an additional 120,000 MT to Spain for 17/18 delivery through their daily reporting s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart